Vaccine · Immune activation · developed by Pfizer
C. difficile vaccine is a toxoid-based Clostridioides difficile vaccine given as an intramuscular injection, in several formulations. It is studied for Clostridioides difficile associated disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05805826 | Phase 1/2 | Clostridoides Difficile Associated Disease | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clostridoides Difficile Associated Disease
Updated Nov 22, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →